Parents might one day give their children a weekly treatment with a nasal spray of virus enzymes to prevent them from getting a severe middle ear infection, based on results of a study done in mice by investigators from St. Jude Children’s Research Hospital and The Rockefeller University, in New York.
Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending the approval of REMICADE(R) (infliximab) for the treatment of severe, active Crohn’s disease (CD) in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy, or who are intolerant to, or have contraindications for, such therapies.
A compound found in blueberries shows promise of preventing colon cancer in animals, according to a joint study by scientists at Rutgers University and the U.S. Department of Agriculture.
A fibrous protein called fibrinogen, found in circulating blood and important in blood clotting, can promote multiple sclerosis (MS) when it leaks from the blood into the brain, triggering inflammation that leads to MS-related nerve damage.
Psychiatric researchers at The Zucker Hillside Hospital campus of The Feinstein Institute for Medical Research have uncovered evidence of a new gene that appears to increase the risk of developing schizophrenia, a disorder characterized by distorted thinking, hallucinations and a reduced ability to feel normal emotions.
Antibiotics are prescribed for approximately 82 percent of acute sinus infections and nearly 70 percent of chronic sinus infections, despite the fact that viruses are by far the most frequent cause of this condition, according to a report in the March issue of Archives of Otolaryngology — Head & Neck Surgery, one of the JAMA/Archives journals.
Shire plc today announced the availability of LIALDATM (mesalamine) with MMXTM Technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), a type of inflammatory bowel disease. LIALDA is the first and only FDA-approved once daily oral formulation of mesalamine. The US Food and Drug Administration approved LIALDA on Jan. 16, 2007.
A drug used to strengthen bone has been found to help reduce the high incidence of hip fractures among people with Parkinson disease, according to a study published in the March 20, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.
AstraZeneca announced that its collaboration partner AtheroGenics, Inc. (Nasdaq: AGIX) revealed first results from the ARISE (Aggressive Reduction of Inflammation Stops Events) phase III clinical outcomes trial which studied AGI-1067, an investigational anti-atherosclerotic agent with antioxidant and anti-inflammatory effects, in patients with coronary artery disease (CAD).
Many would assume that “mounting an immune response” or “having your body fight the cancer” is a good thing. Now, research at the University of California, San Diego (UCSD) School of Medicine strongly suggests that inflammation associated with the progression of tumors actually plays a key role in the metastasis of prostate cancer.